تأثير مشابهات السوماتوستاتين طويلة الأمد في مستويات هرمون النمو عند مرضى ضخامة النهايات بعد الجراحة غير التامة

Abstract EN

Background & Aim : Acromegaly is a rare clinical syndrome associated with high levels of growth hormone.

The most common cause is a tumor (adenoma) secreting growth hormone from the anterior pituitary (representing 95% of the causes).

Surgical treatment -especially Trans-sphenoidal surgery- is the first line therapy for acromegaly but due to the variation of its successful rates.

there is a need to study the role of medical treatment in improving the results after incomplete surgery.

This research aim to study the effect of long acting somatostatin analog -Octreotide- in reducing Growth hormone (GH) and Insulin-like growth factor (IGF-1) levels at the end of treatment.

Methods : A retrospective study included 30 patients diagnosed with acromegaly who had unsuccessful surgery -whether trans-sphenoidal or trans-cranial- admitted to the endocrinology department at Al-Mowasat University Hospital in Damascus to be treated with long-acting Octreotide 30 mg monthly.

Hormonal evaluation for Growth hormone (GH) and Insulin-like growth factor (IGF-1) had been done at baseline after 3 months and at the end of treatment duration, which ranged from 5-11 months (mean of 6.4 months).

Results : There was a strong statistically effect of Octreotide in reducing mean basal levels of GH and IGF-1 at the end of treatment and achieving GH control (GH less than 2.5 ng/ml) in 40%.

IGF-1 control (normal for age and sex) in 40% and complete control (GH < 2.5 ng/ml with normal IGF-1) in 33.3% of patients.

A significant decrease of GH and IGF-I levels was accomplished by the third month compared to baseline levels.

Conclusion : There is an important role of Octreotide in hormonal control and decreasing GH and IGF-1 levels especially after three months of treatment.